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Background: Genetic variations in TGFB1 gene have been studied in relation to coronary heart disease (CHD) risk,
but the results were inconsistent.
Methods: We performed a systematic review of published studies on the potential role of TGFB1 genetic variation
in CHD risk. Articles that reported the association of TGFB1 genetic variants with CHD as primary outcome were
searched via Medline and HuGE Navigator through July 2011. The reference lists from included articles were
also reviewed.
Results: Data were available from 4 studies involving 1777 cases and 7172 controls for rs1800468, 7 studies
involving 5935 cases and 10677 controls for rs1800469, 7 studies involving 6634 cases and 9620 controls for
rs1982073, 5 studies involving 5452 cases and 9999 controls for rs1800471, and 4 studies involving 5143 cases and
4229 controls for rs1800472. The pooled odds ratios (ORs) for CHD among minor T allele carriers of rs1800469,
minor C allele carriers of rs1982073, and minor C allele carriers of rs1800471 versus homozygous major allele carriers
was 1.14 (95% confidence interval [CI]: 1.05-1.24), 1.18 (95% CI: 1.04-1.35), and 1.16 (95% CI: 1.02-1.32), respectively.
No substantial heterogeneity for ORs was detected among the included Caucasian populations for all SNPs.
However, for rs1800471, the statistical significance disappeared after adjusting for potential publication bias. No
significant association was found between rs1800468 and rs1800472 variants and CHD risk.
Conclusion: Minor allele carriers of two genetic variants (rs1800469 and rs1982073) in TGFB1 have a 15% increased
risk of CHD.Background
Transforming growth factor-β1 (TGFβ1) is a ubiqui-
tously expressed multifunctional cytokine that is
involved in many physiological and pathological pro-
cesses. TGFβ1 has been demonstrated to be of funda-
mental importance in the development, physiology and
pathology of the vascular system. Research into the
mechanisms of TGFβ1 signaling over the past two dec-
ades has led to the development of a well-accepted ca-
nonical signaling cascade involving heterotetrameric
complexes of type I and type II serine/threonine-kinase
transmembrane receptors together with Smad* Correspondence: kevin.lu@wur.nl
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reproduction in any medium, provided the ortranscription factors that act as intracellular signaling
effectors. However, the exact mechanisms by which
TGFβ1 signaling exerts its effects within the vasculature
are still incompletely understood [1-4]. According to the
literature [2-7], TGFβ1 can be secreted by several cell
types, including peripheral blood mononuclear cells,
macrophages, platelets, endothelial cells, vascular
smooth muscle cells (VSMCs), myofibroblasts, and renal
cells. Its regulatory function on the vessel wall is direc-
ted at endothelial cells, VSMC and extracellular matrix
[1-3,5-8]. Although the role of TGFβ1 in the pathogen-
esis of atherosclerosis is being recognized, the associ-
ation between plasma TGFβ1 levels and coronary heart
disease (CHD) risk is still controversial [6,9-11]. There
may be several explanations for the controversy: 1),
TGFβ1 is a bimodal regulator of both endothelial cells
and VSMC proliferation, depending on local TGFβ1
levels, cell density, and/or membrane TGFβ receptorsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CHD may differentially affect the biological effects of
TGFβ1 [1,3,10]; and 3), circulating TGFβ1 levels may
not reflect the real vascular interstitial TGFβ1 levels
that are directly involved in the pathogenesis of CHD
[3-5,13]. Also, animal-model studies of CHD reported
inconsistent findings on the role of TGFβ1 in CHD
development. This might, however, be due to the dys-
regulated systemic immune function from different
methods used, i.e. injecting TGFβ1 antibodies, infusing a
soluble TGFβ receptor, or using transgenic or knockout
mice [6,8].
Although the amino acid sequence of the active form
of TGFβ1 is highly conserved across mammalian species
[7,14,15], common TGFB1 genetic variations that could
cause variable constitutive or induced expression of
TGFB1 or protein structural changes and, as a result,
changed TGFβ1 activity, have been identified. They in-
clude rs1800468 (−800 G/A) and rs1800469 (−509 C/T)
in the promoter region, rs1982073 (868 T/C, Leu10Pro)
and rs1800471 (913 G/C, Arg25Pro) in the signal pep-
tide region, and rs1800472 (11929 C/T, Thr263Ile) in the
region encoding the precursor part of the protein [4,15-19].
These genetic variants are generally in strong linkage
disequilibrium (LD) with each other, and this DNA
LD block covers the whole 5′ proximal region of the
TGFB1 gene in Caucasian populations [4,14,16,17].
The minor alleles of these genetic variants or the haplo-
types where the minor alleles are located, were associated
with increased CHD risk in some [11,16,20], but not all
studies [10,14,21,22], and even an opposite association has
been observed [23]. This may partly be explained by a
relatively small sample size, different CHD endpoints and/
or different study populations in each of the published
studies. Demonstrating an association may require a much
larger number of subjects, which may be beyond the re-
source of one single study. Multiple replicated loci have
recently been identified from genome-wide association
(GWA) studies of CHD. However, they together explain
only a small part of its heritability [24,25]. It has been sug-
gested that the adopted highly stringent statistical criteria
and/or the imperfect coverage of genetic variants by
current GWA studies might prevent the discovery of po-
tential loci associated with CHD risk [26]. No meta-
analysis describing TGFB1 genetic variants in relation to
CHD risk exists; therefore, we performed a meta-analysis
of published data that tested for TGFB1 genetic variants
associated with CHD risk.
Methods
Selection criteria
For inclusion, studies 1) had to be case–control or co-
hort in design, 2) examined the association between
TGFB1 gene polymorphisms and primary outcomes ofCHD, coronary artery disease or myocardial infarction
(MI), 3) used validated coronary heart disease pheno-
types (diagnostic criteria included angiographical con-
firmation; elevations of cardiac enzymes, changes of
electrocardiographic and clinical symptoms according to
the World Health Organizations criteria; a documented his-
tory of coronary artery bypass graft, percutaneous trans-
luminal coronary angioplasty, or percutaneous coronary
intervention), and 4) involved unrelated participants.
Search strategy
All studies reporting on the association between TGFB1
gene polymorphism and CHD risk published before July
2011 were identified by comprehensive electronic
searches of Medline and HuGENet. Terms used for the
searches were “TGFB1,” “ischemic heart disease,” “cor-
onary heart disease,” “coronary artery disease,” “acute
coronary syndrome,” “myocardial infarction,” and “an-
gina pectoris” combined with “gene,” “genetic,” “variant,”
“mutation” or “polymorphism.” Hand searches for
related articles among the reference lists of included
articles were also performed. If essential information of
a study was not presented in the publication, authors
were contacted for details. The study was excluded if the
information could not be obtained. In addition, the rele-
vant data from the two latest large-scale meta-analyses
of CHD GWA studies (PROCARDIS [25] and CARDIo-
GRAM [24]; Additional file (1)) were also included for
part of the analysis.
Data extraction
The first author, published year, country, study popula-
tion, mean age of participants, gender distribution, study
design, sample size, outcome, diagnostic criteria, geno-
typing method, characteristics of the controls, allele fre-
quencies, and genotype distributions were extracted. In
PROCARDIS [25] and CARDIoGRAM [24], the studied
SNPs were not available in the genome-wide genotyping
assay and had to be imputed. The SNPs imputed with
high quality (MACH_R2 > 0.3) were included in the
analyses.
Statistical analysis
Deviance from Hardy-Weinberg equilibrium (HWE) was
assessed for the controls of each study using Fisher’s
exact test. For an Iranian study [11], only data on
rs1982073 was utilized in the meta-analysis because
other SNPs deviated from HWE. Genotype distributions
of controls for studies with case–control design or the
entire group for studies with cohort design were used to
estimate the frequency of the putative risk allele for each
SNP using the inverse variance method (Additional file 2)
[27]. Crude ORs with 95% confidence intervals (CI) were
used to evaluate the association between genetic
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lated for several genetic models, i.e. the co-dominant
model, the dominant model, and the recessive model.
Since the co-dominant model effects (or additive model
effects) cannot be straightforward calculated from the
extracted summary data from each study, we presented
the effects of two groups of genotype comparison
(Additional file 2). Since the using of best-guess genotype
from the genotype imputation process can lead to both
false positives and loss of power [28], the allele effects
from the PROCARDIS [25] and CARDIoGRAM [24]
studies were only included in part of the co-dominant
model analyses (Additional file 2). Statistical heterogeneity
in the ORs across studies was assessed with the Q-test. If
there was heterogeneity, ethnicity as source of heterogen-
eity was explored by pooling the data from Caucasian
populations only. If there was no heterogeneity, the fixed-
effect model was used to evaluate the overall gene effect;
otherwise, the random-effect model was used. Presence of
publication bias was explored with Begg’s funnel plot and
Egger’s regression test. If potential publication bias existed,
the Duval and Tweedie nonparametric “trim and fill”
method [29] was used to adjust for it. All reported p
values were two-tailed, and statistical significance was
defined at the α= 0.05 level. All analyses were performed
with the R metafor package [30].
Results
Study inclusion and characteristics
Fifteen citations were identified through the original lit-
erature search; none were meta-analyses [10,11,14,16,20-
23,31-37]. After full review, two studies were excluded
because they were conducted in patient cohorts with a
composite end-point that included CHD [31,32]. Three
studies (two European [10,33] and one Japanese [34])
were conducted without “proper” controls of no CHD
history and were also excluded. One additional Chinese
study met the inclusion criteria but was excluded due to
unavailability of essential information even after con-
tacting the authors [35]. The 9 remaining studies,
together with PROCARDIS [25] and CARDIoGRAM
[24] studies, were included in the meta-analysis (Table 1)
[11,14,16,20-23,36,37].
Quantitative synthesis
None of the genetic variants were associated with CHD
risk when applying a recessive model (data not shown).
Rs1800468 and rs1800472 were not associated with
CHD in either co-dominant or dominant model
(Additional file 2).
For rs1800469, both the CT genotype in the co-
dominant model and the presence of the minor T allele
in the dominant model conferred a risk for CHD when
compared to the common CC genotype (OR= 1.14, 95%CI: 1.04-1.25; and OR=1.14, 95% CI: 1.05-1.24, respect-
ively). The TT genotype conferred a non-significant risk
of similar magnitude (Figure 1). For rs1982073, the TC
genotype conferred a risk for CHD in the co-dominant
model (OR= 1.18, 95% CI: 1.08-1.28), but the CC geno-
type did not when compared to the common TT geno-
type (Figure 2). Under a dominant model, the presence
of the minor C allele was associated with a 1.18 times
increased risk for CHD (Additional file 2).
For rs1800471, both the GC genotype in the co-
dominant model and the presence of the minor C allele
in the dominant model conferred a risk for CHD when
compared to the common GG genotype (OR= 1.15, 95%
CI: 1.01-1.31; and OR=1.16, 95% CI: 1.02-1.32, respect-
ively). The CC genotype conferred a 1.25 times increased
risk, but this was not statistically significant (Figure 3).
After adjusting for multiple testing using Bonferroni
correction, all significant associations for rs1800469 and
rs1982073 under the co-dominant and dominant models
remained. However, for rs1800471, associations were no
longer statistically significant (p > 0.017 in Additional
file 2). When the relevant allele effects from the
PROCARDIS [25] and CARDIoGRAM [24] studies were
included in the co-dominant model analyses, the afore-
mentioned associations attenuated; however, the associ-
ation for rs1982073 persisted (Additional file 2).
No substantial heterogeneity for the ORs was detected
among the included Caucasian populations (Additional
file 2). For rs1982073, however, some heterogeneity existed
between Caucasian populations and non-Caucasian popula-
tions with regard to both CC and CC+TC vs. TT contrasts
(Additional file 2).
Sensitivity analysis and publication bias
To evaluate the influence of the individual studies on
the pooled ORs for rs1800469, rs1982073 and
rs1800471, each time, a single study involved in the
meta-analysis was deleted. The Rotterdam study [21]
and the Japanese study [23] tended to attenuate the
pooled ORs in the co-dominant model for rs1800469
and rs1982073, respectively (Additional file 3). No sub-
stantial alteration in the observed pooled ORs was
observed for rs1800471 (Additional file 3). Begg’s funnel
plot and Egger’s regression test were performed to assess
potential publication bias for rs1800469, rs1982073 and
rs1800471. Although the P values for Egger’s regression
tests for all investigated models were > 0.05, Begg’s fun-
nel plot still suggested a certain degree of publication
bias, potentially from small studies with significant posi-
tive results (Additional file 4). After performing the
“trim and fill method” to adjust for potential publication
bias, the results for rs1800469 and rs1982073 did not
change significantly (data not shown). However, for
Table 1 Characteristics of studies included in the meta-analysisa
Study Country Design Cases Controls Outcome
Genotypes Genotypes p_HWE c
rs1800468 (−800 G/A) N GG AG AA N GG AG AA
Crobu et al, 2008 [22] Italy CC 201 175 25 1 201 168 31 2 0.65 MI
Sie et al, 2006 [21] Netherlands CO 358 288 66 4 6098 5071 984 43 0.58 MI
Syrris et al,1998 [14] England CC 655 541 110 4 244 207 36 1 1 CAD
Cambien et al,1996 [16] FR and NIE CC 563 472 88 3 629 534 89 6 0.28 MI
rs1800469 (−509 C/T) CC CT TT CC CT TT
Sudomoina et al, 2010 [36] b Russia CC 264 77 150 37 212 90 103 19 0.22 MI
Drenos et al, 2009 [37] England CC 240 120 100 20 2143 1090 885 168 0.56 CAD
Crobu et al, 2008 [22] Italy CC 201 67 87 47 201 80 92 29 0.76 MI
Koch et al, 2006 [20] Germany CC 3657 1581 1659 417 1211 564 508 139 0.13 MI
Sie et al, 2006 [21] Netherlands CO 355 171 156 28 6037 3043 2441 553 0.05 MI
Syrris et al, 1998 [14] England CC 655 301 284 70 244 124 97 23 0.54 CAD
Cambien et al, 1996 [16] FR and NIE CC 563 240 257 66 629 263 297 69 0.29 MI
rs1982073 (868 T/C) TT TC CC TT TC CC
Najar et al, 2011 [11] Iran CC 900 301 424 175 900 395 403 102 1 MI
Crobu et al, 2008 [22] Italy CC 201 55 88 58 201 69 101 31 0.66 MI
Koch et al, 2006 [20] Germany CC 3657 1235 1802 620 1211 458 565 188 0.55 MI
Sie et al, 2006 [21] Netherlands CO 343 135 164 44 5844 2322 2698 824 0.37 MI
Yokota et al, 2000 [23] Japan CC 315 89 185 41 591 149 295 147 1 MI
Syrris et al, 1998 [14] England CC 655 242 306 107 244 102 109 33 0.68 CAD
Cambien et al, 1996 [16] FR and NIE CC 563 181 277 105 629 225 297 107 0.62 MI
rs1800471 (913 G/C) GG GC CC GG GC CC
Drenos et al, 2009 [37] England CC 234 187 45 2 2071 1723 331 17 0.78 CAD
Koch et al, 2006 [20] Germany CC 3657 3149 486 22 1211 1063 141 7 0.33 MI
Sie et al, 2006 [21] Netherlands CO 343 297 45 1 5844 4992 823 29 0.51 MI
Syrris et al, 1998 [14] England CC 655 558 95 2 244 214 30 0 0.61 CAD
Cambien et al, 1996 [16] FR and NIE CC 563 464 92 7 629 546 81 2 1 MI
rs1800472 (11929 C/T) CC CT TT CC CT TT
Drenos et al, 2009 [37] England CC 241 234 7 0 2145 2052 89 4 0.02 CAD
Koch et al, 2006 [20] Germany CC 3657 3421 231 5 1211 1138 72 1 1 MI
Syrris et al, 1998 [14] England CC 655 622 33 0 244 237 7 0 1 CAD
Cambien et al, 1996 [16] FR and NIE CC 590 563 27 0 629 585 42 2 0.20 MI
FR and NIE, France and Northern Ireland; CC, case–control; CO, cohort; MI, myocardial infarction; CAD, coronary artery disease.
a, For rs1800468, rs1982073 and rs1800471, 10090 additional subjects were included for the co-dominant model analysis from the PROCARDIS study [25]; for
rs1800469, additional 10090 and 80016 subjects were included for the co-dominant model analysis, respectively from the PROCARDIS study [25] and the
CARDIoGRAM study [24] (Additional file 2).
b, Additional unpublished data have been included.
c, The p values for Hardy-Weinberg equilibrium were derived from Fisher’s exact test.
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dominant and dominant models disappeared (P= 0.07).
Discussion
Several studies have been carried out to test the hy-
pothesis that genetic polymorphisms in the TGFB1
gene including rs1800468, rs1800469, rs1982073,
rs1800471 and rs1800472 might be associated with
CHD risk, but data have yielded conflicting results.
Possible concerns in genetic association studies arethat a positive association might be spurious, while a
negative result might be due to a small sample size.
In this meta-analysis, we incorporated all eligible
studies to date and provided some evidence that
rs1800469 and rs1982073 in the TGFB1 gene are
associated with CHD risk in Caucasian populations.
The inconsistency between the previously reported
results for these SNPs might be due to the small
sample sizes in most of the studies, especially in com-
bination with a modest effect.
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Figure 1 Meta-analysis for coronary heart disease risk depending on the rs1800469 (−509 C/T) polymorphism in the TGFB1 gene. ORs
and corresponding 95% confidence intervals (CIs) are shown. Fixed effects were reported because no significant heterogeneity between studies
was observed. A. Comparison of the homozygous TT genotype with the wild type CC genotype (p= 0.08); B. Comparison of the heterozygous CT
genotype with the wild type CC genotype (p= 0.004); C. Comparison of the TT + CT genotype with the wild type CC genotype ( p= 0.003).
Lu et al. BMC Medical Genetics 2012, 13:39 Page 5 of 9
http://www.biomedcentral.com/1471-2350/13/39Circulating TGFβ1 levels are predominantly under
genetic control with a heritability of 0.54 [17]. Both the
CHD-associated minor risk alleles of rs1800469 and
rs1982073 correlate with an increase in gene expression,
TGFβ1 secretion, and plasma TGFβ1 levels
[4,11,15,17,19,23]. These similar observations might be
due to the strong LD between them [4,14,16,17]. Shah
et al. [18] demonstrated exclusively in vivo and in vitro
recruitment of transcription regulator AP1 to -509 C
(the major non-risk allele of rs1800469) leading to tran-
scriptional repression of the TGFB1 gene. However, the
exact functional variant in this gene region merits fur-
ther identification. In support of the aforementioned
positive association between CHD risk alleles of TGFB1
and increased TGFβ1 production, increased TGFβ1
levels were observed in different stages of plaque devel-
opment in some histological studies [7,38-40]. In 1.23 [  0.85 ,  1.77 ]RE Model
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Figure 2 Meta-analysis for coronary heart disease risk depending on
and corresponding 95% confidence intervals (CIs) are shown. A. Compariso
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p= 0.0002); C. Comparison of the CC+ TC genotype with the wild type TTaddition, enhanced TGFβ1 signalling is established to
cause cartilaginous metaplasia of vascular media and
progressive intima-media thickening after vascular injur-
ies [2-5,7,8,12]. Interestingly, an increased TGFβ1 regu-
lated gene expression was observed in both
atherosclerotic and restenotic lesions [41]. Recently, the
TGFβ1 signalling pathway is suggested to be involved in
the genetic determining of CHD for the most replicated
9p21.3 locus [42-44]. A genetic variant in the SMAD3
gene that encodes one of the downstream activating
transcriptional mediators (Smad3) of TGFβ1 signalling
[1,2] was associated with CHD risk in a GWA study
[44], which was recently replicated in a large-scale meta-
analysis of CHD studies [45].
It has previously been shown that abnormal enlarge-
ment of human coronary arteries (positive remodelling
and aneurysmal coronary lesions) occurs in response to 1.18 [  1.08 ,  1.28 ]
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Figure 3 Meta-analysis for coronary heart disease risk depending on the rs1800471 (913 G/C) polymorphism in the TGFB1 gene. ORs
and corresponding 95% confidence intervals (CIs) are shown. Fixed effects were reported because no significant heterogeneity between studies
was observed. A. Comparison of the homozygous CC genotype with the wild type GG genotype (p= 0.49); B. Comparison of the heterozygous
GC genotype with the wild type GG genotype (p=0.03); C. Comparison of the GC+CC genotype with the wild type GG genotype (p= 0.02).
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related with future acute coronary syndromes and car-
diac events [50,51]. A strong heritable component
(h2= 0.52) of such abnormal enlargement of the coron-
ary artery in the pathogenesis of coronary artery disease
was observed, especially in the proximal coronary artery
[52,53]. Interestingly, the 9p21.3 locus is also associated
with increased risk of abdominal aortic aneurysm [54-56]
and intracranial aneurysm [57,58]. Recently, high plasma
TGFβ1 levels have been implicated in the manifestation of
aortic root dilation in Marfan syndrome [6,13,59]. Fur-
thermore, genetic variations along the TGFβ1 signalling
pathway are associated with coronary artery aneurysm for-
mation and aortic root dilation in Kawasaki diseases [60],
whereas mutations in genes of TGFβ1 signalling pathway
(TGFBR1, TGFBR2 [61,62], and SMAD3 [63]) or TGFβ1
inhibitor genes [64] are implicated in familial or syn-
dromic forms of thoracic aortic aneurysms and dissection.
Taken together, this points at altered vascular remodelling
from increased TGFβ1 signalling in the pathogenesis of
CHD. However, given the fact that TGFβ1 is produced by
multiple lineages of resident cells in vascular wall and ath-
erosclerotic lesion and the fact that it acts in an autocrine,
paracrine, and endocrine fashion [4], it has been very diffi-
cult to pinpoint the exact cellular sources of TGFβ1 that
are relevant for the pathogenesis of CHD. More research
on this topic is warranted.
Some limitations of this meta-analysis should be
acknowledged. First, a relatively small number of studies
for each SNP was included, and therefore we cannot rule
out heterogeneity completely in Caucasian populations al-
though most of the P values for Q-tests were > 0.05. Sec-
ond, the results in the co-dominant model for rs1800469
and rs1982073 were dominated by the Rotterdam [21]
and the Japanese study [23] as shown by the sensitivityanalysis. However, this did not affect our main conclu-
sions. Third, the potential publication bias of relatively
small sample-sized studies might have affected the
results, as there might be eligible studies with negative
results that were not published. In the context of these
limitations, our current results should be interpreted
with caution.
Conclusion
In conclusion, the present study demonstrates an associ-
ation between rs1800469 and rs1982073 in the TGFB1
gene and CHD risk in Caucasian populations. Enhanced
TGFβ1 signalling may therefore be involved in the
pathogenesis of CHD.
Additional files
Additional file 1: Additional acknowledgments for the PROCARDIS
study and the CARDIoGRAM study.
Additional file 2: Table S1. Summary of the meta-analysis of studies
examining the association between TGFB1 polymorphisms and coronary
heart disease risk.
Additional file 3: Table S2. Results from the leave-1-out sensitivity
analysis.
Additional file 4: Figure S1. Funnel plots with pseudo 95% confidence
intervals for rs1800469 analysed according to different genotype
contrasts. A. Comparison of the homozygous TT genotype with the wild
type CC genotype (fixed-effect model, p for Egger’s regression test =
0.05); B. Comparison of the heterozygous CT genotype with the wild type
CC genotype (fixed-effect model, p for Egger’s regression test = 0.61); C.
Comparison of the TT+CT genotype with the wild type CC genotype
(fixed-effect model, p for Egger’s regression test = 0.22). Figure S2.
Funnel plots with pseudo 95% confidence intervals for rs1982073
analysed according to different genotype contrasts. A. Comparison of the
homozygous CC genotype with the wild type TT genotype (random-
effect model, p for Egger’s regression test = 0.94); B. Comparison of the
heterozygous TC genotype with the wild type TT genotype (random-
effect model, p for Egger’s regression test = 0.50); C. Comparison of the
variant genotype of CC+TC with the wild type TT genotype (random-
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http://www.biomedcentral.com/1471-2350/13/39effect model, p for Egger’s regression test = 0.71). Figure S3. Funnel
plots with pseudo 95% confidence intervals for rs1800471 analysed
according to different genotype contrasts. A. Comparison of the
homozygous CC genotype with the wild type GG genotype (fixed-effect
model, p for Egger’s regression test = 0.75); B. Comparison of the
heterozygous GC genotype with the wild type GG genotype (fixed-effect
model, p for Egger’s regression test = 0.89); C. Comparison of the variant
genotype of CC+GC with the wild type GG genotype (fixed-effect model,
p for Egger’s regression test = 0.83).
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